MAP2K1 and melanoma: The success of RAS/MAPK signaling inhibitors in the treatment of melanoma has promoted the further development of such inhibitors, and a variety of novel inhibitors have entered clinical trials.345,346 Typically, pimasertib (AS703026) is a highly selective ATP non-competitive allosteric inhibitor of MEK1/2.